Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Repros Therapeutics Inc    RPRX   US76028H2094

News SummaryMost relevantAll newsSector news 

Repros Therapeutics Inc : NASDAQ:RPRX and NASDAQ:AMRN added to Biotech Stock Watch List

03/28/2013 | 09:40am US/Eastern

New York, NY - Growing Stock Report initiates a NASDAQ Biotech Stock Watch List adding Repros Therapeutics Inc. (NASDAQ:RPRX) and Amarin Corporation plc (NASDAQ:AMRN).

Repros Therapeutics Inc. (NASDAQ:RPRX) a development stage biopharmaceutical company that engages in the development of new drugs to treat hormonal and reproductive system disorders is currently up (+70.54%) today on over 88,000,000 shares traded after the drug developer said its potential low testosterone treatment Androxal met both goals mandated by the Food and Drug Administration in a late-stage trial. Repros Therapeutics Inc. (NASDAQ:RPRX) said Wednesday after markets closed that initial results from the study showed that more than enough patients taking the drug had total testosterone levels that fell within a normal range at the end of 12 weeks of treatment. This news and increase in the stock price has prompted Growing Stock Report to add Repros Therapeutics Inc. (NASDAQ:RPRX) to their NASDAQ Biotech Stock Watch List.

To see what other Investors are saying about Repros Therapeutics Inc. (NASDAQ:RPRX)

Click Here:

Amarin Corporation plc (NASDAQ:AMRN) a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases is currently up (+3.39%) after bouncing off it's recent 52 week low of $6.77 after a recent report that said weekly Vascepa prescription growth is decelerating at a time when it should be doing the opposite. The number of patients going back for Vascepa refills is also lower than expected. Total Vascepa prescriptions were 1,240, up 14% from the week of March 8. Numerically, Vascepa scripts are growing but the rate of growth has dropped for four weeks straight. Week-over-week script growth was 33% for the week ended Feb. 22, down to 14% for the week of March 15. This bounce in Amarin Corporation plc (NASDAQ:AMRN) has prompted Growing Stock Report to add the stock to their NASDAQ Biotech Stock Watch List.

To see what other Investors are saying about Amarin Corporation plc (NASDAQ:AMRN)

Click Here:

Also mentioned in their NASDAQ Biotech Stock Watch List was Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) which is currently up (+1.89%) as of this writing.

To see what other Investors are saying about Keryx Biopharmaceuticals Inc. (NASDAQ:KERX)

Click Here: monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here:

Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit website, for complete risks and disclosures.

Contact Info:
Growing Stock Report

© Accesswire 2013
React to this article
03/17 REPROS THERAPEUTICS : R) Reports Fourth Quarter and Year End 2014 Financial Resu..
03/16 REPROS THERAPEUTICS : reports 4Q loss
03/16 REPROS THERAPEUTICS : R) Reports Fourth Quarter and Year End 2014 Financial Resu..
02/12 REPROS THERAPEUTICS : Patent Application Titled "Selective Estrogen Receptor Mod..
02/10 REPROS THERAPEUTICS : Change in Directors or Principal Officers (form 8-K)
02/02 Repros Submits New Drug Application to FDA for Androxal (R)
01/12 REPROS THERAPEUTICS : Regulation FD Disclosure (form 8-K)
2014 REPROS THERAPEUTICS : RPRX) Issues Update on Androxal's Global Regulatory Status
2014 Repros Updates Androxal(R) Global Regulatory Status
2014 Repros Initiates Two Phase 2B Uterine Fibroid Studies
Duration : Period :
Repros Therapeutics Inc Technical Analysis Chart | RPRX | US76028H2094 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes